Feline leukemia virus (FeLV), like other naturally occurring retroviruses, is characterized by a high degree of genetic diversity. FeLV-945 is a natural isolate derived from non-B-cell non-T-cell lymphomas classified anatomically as multicentric. FeLV-945 exhibits a unique structural motif in the LTR composed of a 21-bp tandem triplication downstream of a single copy of enhancer. The unique FeLV-945 LTR is precisely conserved among eight independent multicentric lymphomas collected in a geographic cluster. Previous studies using reporter gene constructs predict that the FeLV-945 LTR would confer a replicative advantage on the virus that contains it, particularly in primitive hematopoietic cells. Such an advantage may account for the precise conservation of the unique LTR sequence. To test that prediction, a set of recombinant, infectious FeLVs was developed that are isogenic other than the presence of the FeLV-945 LTR or mutations of it. Replication assays show that the FeLV-945 LTR confers a distinct growth advantage in K-562, FEA, and 3201 cells and implicate the 21-bp triplication in that function. Replacement of two copies of the triplicated element with random sequence greatly diminished the replicative capacity, thus implicating the triplicated sequence itself in LTR function. The 21-bp triplication was shown to contain specific nuclear protein binding sites, which may account for the selective pressure to conserve the sequence.
INTRODUCTION
Retroviruses, like other viruses with RNA genomes, generally do not consist of a single genomic species of defined sequence. Rather the RNA virus population in the natural host can be more accurately described as a mixture of closely related genomes, termed a quasispecies or swarm. During infection in the natural host, the virus population is continually shaped by selective forces. The variable genomic structure of natural RNA virus populations is thought to have significant biological impact because mutations at only a small number of sites may alter the virus phenotype. Such alterations provide the substrate on which selective pressures act to shape the population (Domingo et al., 1985; Katz and Skalka, 1990; Coffin, 1992; Mansky, 1998) .
Natural retrovirus populations, in particular, are characterized by a high degree of genetic diversity. Variant genomes are generated at a high rate during retrovirus replication because of both error-prone reverse transcription and recombination (Katz and Skalka, 1990; Coffin, 1992; Mansky, 1998) . These mechanisms generate genetic variability in natural retrovirus populations, upon which selective forces act to promote the conservation (and sometimes the predominance) of variants with an advantageous phenotype (Katz and Skalka, 1990; Coffin, 1992; Mansky, 1998) . A number of investigators have considered aspects of retrovirus phenotype that may be subject to selective pressure during infection in vivo (reviewed in Katz and Skalka, 1990; Coffin, 1992; Mansky, 1998) . A replicative advantage, for example, may be realized as increased levels of virus in infected tissues or increased kinetics of virus spread. Indeed, it is clear that a replicative advantage does not have to be large to have an impact on retrovirus population dynamics. For example, it has been calculated that a mutation which affords a 1% replication advantage will represent 50% of the virus population within 400 replication cycles, assuming a mutation rate of 10 Ϫ4 (Coffin, 1992) . Alternatively, a mutation may decrease replication, thus prolonging survival of the host. It is further hypothesized that phenotypic advantage may not be replicative at all. For example, a mutation may afford a selective advantage if it promotes survival of the infected cell, e.g., through insertional activation of proto-oncogenes.
Feline leukemia virus (FeLV) is a naturally occurring retrovirus endemic in an outbreeding mammalian species, the domestic cat. In this respect, FeLV infection in its natural host emulates human infections more closely than does retroviral infection in laboratory inbred animals. In fact, FeLV in cats has been widely used as a model to study population dynamics in host-parasite interactions (Courchamp et al., 1997; Fromont et al., 1998) . Like other retroviruses, FeLV is a genetically complex family of closely related viruses subject to selective pressures in the natural host, although the selective advantages conferred by natural variants are not well understood. The variable clinical outcome of FeLV infection, thought to reflect its genetic diversity, includes degenerative diseases like anemia or immunodeficiency as well as proliferative diseases like leukemia and lymphoma (Hoover and Mullins, 1991; Neil et al., 1991; Rezanka et al., 1992) . Molecular analysis of FeLV in natural infections indicates that genetic variations, sometimes minor, may have significant impact on virus phenotype and pathogenesis. Genetic variations most clearly linked to phenotypic change generally occur within the surface glycoprotein gene (SU) or the viral long terminal repeat (LTR) (Hoover and Mullins, 1991; .
The LTR of FeLV is similar in structure to that of the murine leukemia viruses (MuLV) and contains a central enhancer motif that is strongly conserved, structurally and functionally, among mammalian C-type retroviruses (Golemis et al., 1990; Pantginis et al., 1997) . The basic enhancer motif contains a tandem series of binding sites for the nuclear factors LVb/Ets, core enhancer binding protein, nuclear factor 1 (NF-1), and a glucocorticoid response element (Fulton et al., 1990; Neil et al., 1991; Athas et al., 1994) . It is noteworthy that the typical FeLV isolate horizontally transmitted among animals in nature contains only a single copy of the enhancer. In contrast, FeLV proviruses cloned directly from thymic lymphomas typically contain tandemly repeated enhancers, generally in two or three directly repeated copies. The specific enhancer duplication is unique to each isolate but invariably includes a 35-bp domain containing the core binding site (Fulton et al., 1990; Plumb et al., 1991; Matsumoto et al., 1992; Nishigaki et al., 1997) . Analysis of experimental infection with single enhancer-containing virus demonstrates that duplicated enhancers in the FeLV LTR are generated in vivo during passage in a single animal and predominate in thymic lymphomas (Rohn and Overbaugh, 1995) . By comparison, an FeLV variant termed FeLV-945 exhibits a structure unique among FeLV isolates. The LTR of FeLV-945 is unique in two respects: (1) It contains only a single copy of enhancer, unusual for tumor-derived proviruses, and (2) it contains a tandem 21-bp triplication beginning ϳ25-bp downstream of the enhancer (Levesque et al., 1990; Athas et al., 1995a) . FeLV-945 was identified in natural lymphomas classified anatomically as multicentric. Such tumors typically involve lymph nodes, spleen, liver, and kidneys, alone or in any combination, but generally not the thymus (Rezanka et al., 1992) . Multicentric lymphomas in our collection are of non-T-cell non-B-cell origin, unlike the more common thymic tumors of T-cell origin. Although their precise lineage and differentiation state remain unknown, they are thought to represent a lymphoid or other hematopoietic progenitor (Athas et al., 1995a) . It is striking that the sequence and position of the 21-bp triplication are precisely conserved among FeLV-945 LTRs identified in 8 of 11 independent multicentric lymphomas collected in a geographic cluster (Athas et al., 1995a,b) .
Previous studies have been performed to explore the possible role of the 21-bp triplication in the FeLV-945 LTR and the potential selective advantages that may account for its precise conservation. In particular, the ability of the FeLV-945 LTR to modulate reporter gene expression has been compared to that of two other naturally occurring FeLV isolates. The results indicated that the 21-bp triplication provides transcriptional enhancer function to the LTR that contains it and that it functions preferentially in primitive hematopoietic cells (Athas et al., 1995b) . In K-562 cells, a human leukemia cell line considered to be primitive and multipotential (Lozzio et al., 1981; Burger et al., 1992) , the FeLV-945 LTR was shown to be as much as 12-fold more active than other naturally occurring FeLV LTRs examined. Further, the FeLV-945 LTR was shown to be more active in K-562 than in other cells examined. For example, the level of activity of the triplication-containing LTR in K-562 cells was 4.2-fold higher than its activity in FEA cells, a feline embryo fibroblast cell line (Athas et al., 1995b) . A prediction of these findings is that the FeLV-945 LTR confers a replicative advantage on the virus that contains it, especially in primitive hematopoietic cells. This growth advantage may account for the induction of tumors of the type in which FeLV-945 was identified and may represent a selective advantage that contributes to its precise conservation. The experiments reported below were designed to test the prediction that the FeLV-945 LTR confers a replicative advantage and to explore the molecular mechanism of its influence.
RESULTS AND DISCUSSION
A prediction of the findings from previous studies (Athas et al., 1995b) is that the FeLV-945 LTR would confer a growth advantage on the virus that contains it, especially in primitive hematopoietic cells. To test that prediction, a set of recombinant, infectious FeLVs was developed based on the genome of FeLV-B/GardnerArnstein [FeLV-B/GA ]. FeLV-B/GA was chosen for this purpose because members of FeLV subtype B are infectious to human cells; thus, recombinants based on FeLV-B/GA could be used to infect human K-562 as a model for primitive hematopoietic cells. Three recombinant, infectious FeLVs were constructed ( Fig. 1) : GA-945L contains the FeLV-945 LTR (Athas et al., 1995a) , substituted into FeLV-B/GA between conserved EcoRV and KpnI restriction sites. GA-922L contains an EcoRV-HincII fragment of the FeLV-922 LTR (Athas et al., 1995a) , substituted into GA-945L. GA-922L is isogenic with GA-945L except that it contains only a single copy of the 21-bp sequence. GA-61EL contains an EcoRV-HincII fragment of the FeLV-A/61E LTR (Donahue et al., 1988) , substituted into GA-945L. GA-61EL differs from GA-945L in that the LTR contains only a single copy of the 21-bp sequence, in which a nucleotide substitution occurs at position 11 ("A" in GA-945L, "G" in GA-61EL). The FeLV-A/61E LTR also differs at two other nucleotides, both of which are located between the enhancer and the 21-bp triplication. FeLV-A/61E was selected for examination because it represents a naturally occurring isolate of FeLV typical of those horizontally transmitted among cats in nature (Donahue et al., 1988) .
Infectious virus stocks were developed by electroporation of plasmid DNA encoding each recombinant provirus into canine D-17 cells. D-17 cells were chosen to avoid the risk of recombination with endogenous FeLVrelated sequences present in feline, but not canine, cells (Roy-Burman, 1996) . Productive infection was documented by ELISA for FeLV p27gag in culture supernatants (Synbiotics Corp.). Culture supernatants were collected at Day 7 after electroporation and were frozen in aliquots at Ϫ70°C. Infectious titer of each stock was determined by end-point dilution in triplicate on D-17 cells. Infectious titers thus determined were 9 ϫ 10 5 /ml, 5.5 ϫ 10 5 /ml, and 1.9 ϫ 10 6 /ml for GA-945L, GA-922L, and GA-61EL, respectively. Integrity of the recombinant LTR sequence in producer D-17 cells was verified by RT-PCR amplification and nucleotide sequence analysis. Specifically, total cellular RNA was isolated from each producer cell line, reverse transcribed, and amplified by PCR using primers specific for the U3 region of the FeLV LTR (Fig. 1) . Agarose gel electrophoresis of the results demonstrated amplification of a single product of the predicted size in each case. Subsequent cloning and nucleotide sequence analysis demonstrated each recombinant U3 region to be intact and unaltered in producer D17 cells (data not shown).
To test the prediction that the FeLV-945 LTR confers a growth advantage on the virus that contains it, parallel cultures of K-562 cells were infected with equivalent amounts of GA-945L, GA-922L, or GA-61EL. Specifically, 4 ϫ 10 6 K-562 cells, at a density of 2 ϫ 10 5 cells/ml, were incubated with recombinant virus at m.o.i. ϭ 0.001 for 5 h in culture medium with Polybrene added at 8 g/ml. Culture supernatants were harvested periodically thereafter for assay of reverse transcriptase activity. At each collection, 4 ϫ 10 6 cells were reseeded at 2 ϫ 10 5 cells/ml to maintain a relatively constant cell density throughout the experiment. Cells remaining after reseeding also were frozen at each time point for isolation of RNA. The entire experiment was performed in triplicate with each recombinant virus. To assay the reverse transcriptase activity in culture supernatants collected at each time point, virus was pelleted by ultracentrifugation and resuspended for analysis, and at least three serial dilutions of the suspension were analyzed to ensure that data were collected in the linear range of the assay. The results showed that the triplication-containing FeLV-945 LTR, as present in GA-945L, confers a distinct growth advantage in K-562 cells ( Fig. 2A) . At Days 7-11, for example, cells infected with GA-945L are producing from five-to eightfold more virus than cells infected with GA-922L or GA-61EL. By Day 21, however, equivalent
Diagram of the LTR of recombinant FeLVs constructed on the genome of FeLV-B/GA. Indicated are the number of repeats of enhancer, 21-bp sequence, and the positioning of those elements relative to the promoter (Pro). GA-945L is isogenic with GA-922L except for the triplication of a 21-bp sequence. GA-922L and GA-61EL differ as indicated at nucleotide 11 of the 21-bp sequence and also at two other nucleotides located between the enhancer and the 21-bp sequence (not shown). Shown are EcoRV, HincII, and KpnI restriction sites used in construction of the recombinants. Also shown are the positions of oligonucleotide primers LTR13 and LTR14 used in PCR to amplify products of the indicated sizes from recombinant LTRs. numbers of particles are produced. This finding likely reflects the maximal capacity of the culture to produce FeLV once all cells are infected and are maximally producing virus. Thus the replicative advantage conferred by the triplication-containing LTR is seen in the kinetics of virus spread. During the course of the experiment, cellular RNA also was isolated from infected cells collected at each time point. Northern blot analysis of viral RNA expressed in infected cells also demonstrated the growth advantage conferred by the FeLV-945 LTR in K-562 cells, thus confirming the finding by an independent measure (Fig. 2B) . These findings are consistent with previous studies using reporter gene constructs, which showed that the triplication-containing FeLV-945 LTR functions in K-562 cells to a level approximately an order of magnitude higher than the FeLV/A-61E LTR (Athas et al., 1995b) . As described above (Fig. 1) , a naturally occurring polymorphism occurs at nucleotide 11 of the 21-bp sequence ("A" in GA-945L and GA-922L, "G" in GA-61EL). This polymorphism appears not to impact the replication kinetics of the virus because GA-922 and GA-61E are indistinguishable in this assay.
A similar experiment then was performed using feline fibroblasts (FEA), a cell line in which reporter gene assays had previously indicated the function of the FeLV-945 LTR to be 2.6-fold higher than that of FeLV-A/61E (Athas et al., 1995b) . In this experiment, 1 ϫ 10 6 adherent FEA cells were incubated with each recombinant virus at m.o.i. ϭ 0.001 for 5 h in the presence of Polybrene at 8 g/ml. Culture supernatants were harvested periodically FIG. 2. Replication kinetics of GA-945L, GA-922L, and GA-61EL in K-562 cells. (A) Replication kinetics of recombinant FeLVs, as measured by reverse transcriptase activity in culture supernatants. Culture supernatants were collected at 2, 4, 7, 9, 11, and 21 days after infection as indicated. Reverse transcriptase activity was measured on 3-4 serial dilutions of each sample, to ensure that data were collected in the linear range of the assay. The experiment was repeated three times independently. The data shown represent the mean and standard error of triplicate experiments, expressed as cpm/ml of [ 3 H]-TTP incorporated. (B) Northern blot analysis of RNA from K-562 cells infected with GA-945L, GA-922L, or GA-61EL. Total cellular RNA was isolated from infected cells periodically after infection and was examined by Northern blot hybridization (Bonham et al., 1987) with a probe for exogenous FeLV U3 (vRNA). As a loading control, blots were rehybridized to a probe for ␤-actin.
thereafter for assay of reverse transcriptase activity. At each collection, 1 ϫ 10 6 cells were reseeded to maintain a relatively constant cell density throughout the experiment. The entire experiment was performed in triplicate with each recombinant virus. Analysis of reverse transcriptase activity in culture supernatants demonstrated that the FeLV-945 LTR, as represented in GA-945L, confers a 3-fold growth advantage in FEA cells (Fig. 3A) . This advantage is evident as early as Day 6 p.i. and remains throughout the exponentially increasing period of virus spread (through Day 12). Northern blot analysis of viral RNA expressed in infected FEA confirms the growth advantage conferred by the FeLV-945 LTR (Fig. 3B) . The results of these experiments in K-562 and FEA cells are consistent with reporter gene assays performed previously (Athas et al., 1995b) . The studies indicate that the triplication-containing FeLV-945 LTR confers a growth advantage on the virus that contains it and that the advantage is greatest in primitive hematopoietic cells.
In contrast, when the experiment was performed using Jurkat T cells, no growth advantage conferred by the FeLV-945 LTR was detected. Rather, all recombinant FeLVs examined replicated to comparable levels in Jurkat T-cells (data not shown). These findings are inconsistent with previous studies using reporter gene constructs in Jurkat cells, in which the activity of the FeLV-945 LTR was 2-fold higher than that of FeLV-A/61E (Athas et al., 1995b) . A problem in interpreting the present findings, however, is that FeLV replicates very poorly in Jurkat cells. For example, reverse transcriptase assay of Jurkat cell supernatants collected at 21 days p.i. reveals only 4.8 ϫ 10 3 cpm/ml [ 3 H]-TTP incorporated, compared to 2.1 ϫ 10 6 cpm/ml in the same assay performed with infected K-562 cells. Thus the restriction on FeLV repli- Northern blot analysis of RNA from FEA cells infected with GA-945L, GA-922L, or GA-61EL. Total cellular RNA was isolated from infected cells periodically after infection and was examined by Northern blot hybridization (Bonham et al., 1987) with a probe for exogenous FeLV U3 (vRNA). As a loading control, blots were rehybridized to a probe for ␤-actin.
cation in Jurkat cells may obscure any differences in replicative potential of the recombinant viruses. The same experiment performed using MOLT-4, another human leukemia cell line of T-lymphoid origin, revealed a similar restriction on FeLV replication (data not shown). Therefore to explore the potential replicative advantage conferred by the FeLV-945 LTR in T-cells, feline 3201 T-cells were used. Previous studies by others have shown that 3201 cells are resistant to infection with FeLV subtype B (Boomer et al., 1994) probably because these cells express a defective endogenous FeLV envelope protein that blocks exogenous FeLV-B infection (McDougall et al., 1994) . For this reason, our recombinant viruses based on FeLV-B/GA could not be used to examine replication in 3201 cells. Rather we used a plasmid encoding FeLV-A/61E (Donahue et al., 1988) and a previously described recombinant termed 61g945L, in which the LTR of FeLV-A/61E was substituted with that of FeLV-945 (Athas et al., 1995b) . Plasmid DNA (4 g) encoding FeLV-A/61E or 61g945L was introduced by liposomemediated transfection into 4 ϫ 10 6 3201 T-cells growing at a density of 2 ϫ 10 5 cells/ml. Culture supernatants were harvested periodically thereafter for assay of reverse transcriptase activity. At each collection, 4 ϫ 10 6 cells were reseeded at 2 ϫ 10 5 cells/ml to maintain a relatively constant cell density throughout the experiment, and the entire experiment was repeated in triplicate for each virus. Analysis of reverse transcriptase activity in culture supernatants revealed that the FeLV-945 LTR, when substituted into FeLV-A/61E, confers a distinct growth advantage in 3201 T-cells (Fig. 4) . At Day 12, for example, reverse transcriptase activity in supernatants of 61g945L-infected cells is 13-fold higher than in FeLV-A/61E-infected cells (6.5 ϫ 10 4 cpm/ml vs 5 ϫ 10 3 cpm/ml). By Day 18, reverse transcriptase activity in supernatants of 61g945L-infected cells exceeds 10 6 cpm/ ml, a level not reached by FeLV-A/61E-infected cells until Day 25.
These data show that the FeLV-945 LTR confers a growth advantage on the virus that contains it, especially in multipotential hematopoietic cells and in feline T-cells. Because GA-945 and GA-922 are isogenic viruses other than the presence or absence of the 21-bp triplication, a comparison of their replication kinetics directly implicates the 21-bp triplication in the function of the FeLV-945 LTR. Regarding the molecular mechanism by which the 21-bp triplication may function in the context of the FeLV-945 LTR, at least two possibilities have been considered. One possibility is that the triplication contributes genuine enhancer function, perhaps via the binding of nuclear transcription factors. An alternative possibility is that the 21-bp triplication functions to maintain the appropriate spacing in the LTR between the enhancer and the promoter. A spacer function might be particularly relevant in an LTR, like the triplication-containing LTR, in which the enhancer is not tandemly repeated. It is possible that both functions may be served, as is apparently the case with the region termed DEN of the MCF13 LTR Yoshimura, 1994, 1998; Yoshimura et al., 1997) . It is noteworthy that the 42-bp contributed by two additional copies of the 21-bp repeat represent an exact multiple of 10.5 bp per helical turn of DNA, i.e., four whole turns (Rhodes and Klug, 1980; Tullius and Dombroski, 1985) . The stereospecific alignment provided by the triplication could be contributory to enhancer and/or spacer functions as considered recently by others studying the MCF MuLV LTR (Chen and Yoshimura, 1998; DiFronzo and Holland, 1999) . To investigate the mechanism by which the 21-bp triplication influences LTR function, studies were previously performed in which the spacing of LTR elements was disrupted, and the function of such LTRs was examined in reporter gene constructs. Specifically, a restriction fragment containing the enhancer and the 21-bp triplication of the FeLV-945 LTR was removed from its position upstream of the transcriptional promoter and cloned downstream of the reporter gene. An analogous construct was prepared from the LTR of FeLV-A/61E. Reporter gene assays performed in K-562 cells showed that expression modulated by the triplication-containing fragment from FeLV-945 was 3.6-fold higher than that modulated by the analogous fragment from FeLV-A/61E (Athas et al., 1995b) . These experiments suggest that the 21-bp triplication contributes genuine transcriptional enhancer function to the LTR that contains it, but they do not rule out a spacer function. In the present study, additional experiments were performed to examine a possible spacer function more directly. Specifically, the LTR of GA-945L was modified such that two copies of the triplicated 21-bp sequence were replaced with 42 bp of random sequence. This virus is referred to as GA-TripR (Fig. 5) . Plasmids (4 g) encoding GA-945L or GA-TripR were introduced by electroporation into parallel cultures of K-562 cells (4 ϫ 10 6 cells at a density of 2 ϫ 10 5 /ml). Culture supernatants were harvested periodically thereafter for measurement of reverse transcriptase activity. Genomic DNA also was isolated periodically to document stability of the recombinant GA-TripR LTR. Analysis of reverse transcriptase activity in culture supernatants revealed a distinct growth advantage of nearly 2 orders of magnitude for GA-945L compared to GA-TripR. This difference is evident beginning as early as Day 6 after infection (Fig. 6) . Because GA-TripR replicates relatively poorly compared to GA-945L, we anticipated a strong selective pressure in this experiment for any mutant that might arise with increased replicative potential. Thus to confirm the stability of the recombinant GA-TripR LTR during the course of the experiment, the LTR was amplified by PCR from infected cells collected at each time point (beginning at Day 6). Nucleotide sequence analysis of the products showed that the 42-bp insertion in the recombinant LTR is stable in culture for Ն3 weeks, although occasional point mutations are detected. In continuous culture, however, mutants begin to accumulate and, eventually, to predominate. It is interesting that two such mutants had precisely deleted the 42-bp random sequence and had accumulated two to three additional nucleotide substitutions (data not shown). The data shown in Fig. 6 represent collections up to Day 20, a period of time during which the 42-bp random substitution remains intact in the GA-TripR LTR. The results of this experiment show that substitution of the nucleotide sequence of the 21-bp triplication diminishes the ability of the FeLV-945 LTR to direct virus replication, even though spacing and stereospecific alignment were maintained. It is noteworthy that the 42-bp random substitution essentially cripples virus replication (Fig. 6) , whereas the simple deletion of two of the 21-bp repeats diminishes replicative capacity much less drastically (Fig. 2) . These data, along with our previously published findings (Athas et al., 1995a,b) , indicate that the 21-bp triplication does not perform solely a spacer function but that the sequence itself is important. These findings are consistent with the precise conservation of the sequence and position of the triplication within the LTR of independent isolates of FeLV-945. Were the selective pressure solely to conserve appropriate spacing, precise conservation of this particular repeat structure might not be predicted.
The contribution of the specific nucleotide sequence to the function of the 21-bp triplication is not yet known, but one possibility is that the sequence provides sites for the specific binding of nuclear factors. To examine this possibility, electrophoretic mobility shift assays (EMSA) were performed using as probe a 96-bp AluI-HincII restriction fragment of the FeLV-945 LTR containing the 21-bp triplication. The results demonstrated the presence of specific protein-DNA complexes using nuclear extracts prepared from K-562 cells (Fig. 7) . It is not yet known whether the specific binding of these proteins to the 21-bp triplication contributes functionally to the growth advantage conferred by the FeLV-945 LTR. If so, An objective of the present study was to examine selective pressures that shape natural retroviral infection in an outbreeding mammalian host. The findings demonstrate that the FeLV-945 LTR, identified uniquely in non-B-cell non-T-cell feline lymphomas, confers a replicative advantage on the virus that contains it, particularly in primitive hematopoietic cells and in feline T-cells. K-562 has been useful in these studies as a model for multipotential hematopoietic cells. However, K-562 may not be generally representative of primitive hematopoietic cells, and further, cells of human origin do not represent the natural host for FeLV. These limitations point to the necessity of examining the growth advantage conferred by FeLV-945 in vivo, as is planned for future studies. The FeLV-945 LTR contains unique sequence elements that are precisely conserved among independent isolates in a geographic cluster. The present findings indicate that the replicative advantage conferred by the FeLV-945 LTR represents a selective pressure responsible for precise conservation of those sequence elements.
MATERIALS AND METHODS

Viruses and cell lines
Molecularly cloned, infectious proviral DNAs of FeLV used in the study included FeLV-B/Gardner-Arnstein and FeLV-A/61E (Donahue et al., 1988) . Molecular clones of , and the 61g945L recombinant were generated in previous studies (Athas et al., 1995a,b) . The FEA cell line, a continuous line of feline embryonic fibroblasts, was obtained from Jennifer Rojko, The Ohio State University, and was grown in Dulbecco's modified Eagle's culture medium with 10% fetal calf serum (FCS). The human Jurkat T-cell line was obtained from Fayth Yoshimura, Wayne State University, and was grown in RPMI 1640 with 15% FCS. 3201 is an FeLV-negative thymic lymphoma-derived cell line of feline origin (Rojko et al., 1989) and was maintained in RPMI 1640 with 10% FCS. Other cell lines were obtained from American Type Culture Collection including the human malignant hematopoietic progenitor cell line, K-562 (ATCC CCL 243), and the canine osteogenic sarcoma cell line, D-17 (ATCC CCL 183). These cell lines were grown in RPMI 1640 with 10% FCS or Eagle's minimal essential culture medium with 10% FCS, respectively.
Construction of recombinant proviral clones and generation of infectious stocks
Recombinant FeLVs GA/945L, GA-922L, and GA-61EL were constructed from an infectious, molecular clone of FeLV-B/Gardner-Arnstein [FeLV-B/GA ]. A 3-kb BamHI fragment containing the 3Ј terminus of the proviral clone, including the full length of the 3ЈLTR, was subcloned into a plasmid vector. This fragment was modified through a series of stepwise diges- tions and ligations to construct recombinant LTRs. First, the U3 region of the 3ЈLTR of FeLV-B/GA was substituted with that of FeLV-945 (Athas et al., 1995a) between conserved EcoRV and KpnI restriction sites to yield the LTR of GA-945L. That recombinant was further modified by the substitution of an EcoRV-HincII fragment from the U3 region of FeLV-922 (Athas et al., 1995a) or FeLV-A/61E (Donahue et al., 1988) to yield the LTRs of GA-922L and GA-61EL, respectively. The recombinant 3-kb BamHI fragments then were introduced into full-length FeLV-B/GA to yield recombinant proviral clones bearing substitutions in the 3Ј LTR. It is predicted that, by the action of reverse transcriptase, the recombinant LTR would be present at both ends of proviral DNA generated after the first replication cycle. To generate infectious stocks, recombinant proviral DNA (8 g) was introduced into 1 ϫ 10 7 D-17 cells by electroporation (Cell Porator Electroporation System, Life Technologies, Inc.) at 1180 F, 300 V, low ⍀. Productive FeLV infection was monitored periodically thereafter using a commercially available ELISA for FeLV p27gag in culture supernatants (Synbiotics Corp.).
At 7 days after electroporation, supernatant was collected from each culture, confirmed by ELISA to contain FeLV, aliquoted into 1-ml volumes, and frozen at Ϫ70°C. Total cellular RNA was isolated from producer D17 cells as previously described (Athas et al., 1995b) . RNA (5 g) from each infected culture was reverse transcribed using 200 U of RNase H Ϫ Moloney leukemia virus reverse transcriptase (Superscript II; Life Technologies, Inc.) with 100 M random hexamer primers for 30 min at room temperature, followed by 1 h at 37°C and 5 min at 95°C. FeLV LTR sequences were amplified by PCR using primers LTR13 (5Ј-AAAGACCCCCTACCCCAAAAACT) and LTR 14 (5Ј-TGAGGCGGAAGGTCGGACTC) in a 100-l reaction mixture containing 10% of the reverse transcription reaction, 400 ng of each primer, 1.5 mM MgCl 2, and 0.2 mM of each deoxyribonucleotide triphosphate in a Taq polymerase reaction buffer provided by the manufacturer (Promega Corp.). An initial denaturation step at 98°C for 5 min was followed by addition of 5 units Taq DNA polymerase (Promega Corp.) and 35 cycles of denaturation at 94°C for 30 s, 57°C for 30 s, and 72°C for 1 min with a final extension for 15 min in a thermocycler (Robocycler 40; Stratagene). Amplification products were examined by agarose gel electrophoresis and cloned into the pGEM-T plasmid vector (Promega Corp.). Nucleotide sequence analysis was performed using the Sequenase enzyme (Amersham Life Sciences) as described by the manufacturer.
The LTR of GA-TripR was generated from that of GA-922L using spliced-overlap-extension (SOE) PCR (Horton et al., 1990) . SOE primers were designed to insert 42 bp in the LTR of GA-922L, immediately following the single copy of 21-bp sequence of interest. SOE primers used were GAX-b (5Ј-AAGGTTCCGATCCGAACCCTAA-GTATAGCCTGCTGGCAGTGGCCTTG) and GAX-c (5Ј-TTCGGATCGGAACCTTCCCTAACTCTAACTCTCCA-GGCTCCCCAGTT). Nucleotide sequence of the recombinant LTR was verified, and it was introduced into fulllength proviral DNA to generate GA-TripR. For replication assays, proviral DNA encoding GA-TripR was introduced by electroporation as described above into recipient cells. Culture supernatants were collected periodically thereafter, and genomic DNA was prepared as previously described (Bonham et al., 1987 ) from infected cells. The FeLV LTR was amplified from genomic DNA using LTR13 and LTR14 in PCR reactions as described above. Amplification products were cloned into pGEM-T vector and subjected to nucleotide sequence analysis as described above.
Reverse transcriptase assays
Tissue culture supernatants were clarified by filtration through Star LB filters (0.22 m; Costar), and virus was pelleted by ultracentrifugation at 120,000 g for 90 min at 4°C. The pellet was resuspended in 40 mM Tris, pH 8.1; FIG. 7 . Electrophoretic mobility shift assays (Feghali et al., 1994) performed using as probe a radiolabeled 96-bp AluI-HincII fragment of the FeLV-945 LTR containing the 21-bp triplication. Binding reactions contained radiolabeled probe (1 ng) and nuclear extract (3.5 g) from K-562 cells. Included in the reactions as indicated was cold DNA probe as specific competitor, or HindIII/HaeIII-digested bacteriophage DNA as nonspecific competitor, at 250-fold molar excess. Specific complex formation is seen in lanes 2 and 4. 50 mM KCl; 20 mM dithiothreitol; and 0.2% NP-40. The virus suspension, or dilutions of it in the same buffer, was added 1:1 to a solution of 40 mM Tris, pH 8.1; 50 mM KCl; 2 mM MnCl 2 ; 0.04 mg/ml poly(A)-oligo(dT) 15 (Boehringer-Mannheim); and 100 Ci/ml methyl-[ 3 H]-TTP (20 Ci/mmol; NEN-DuPont) and incubated at 37°C for 1 h. The entire reaction was spotted onto a DE-81 filter disk (Whatman), air-dried, and washed four times, 5 min each, in 0.5 M Na 2 HPO 4 , followed by 5 min in 95% ethanol. Filters were dried and incorporated [ 3 H]-TTP quantified by liquid scintillation counting in ScintiVerse E (Fisher). A series of at least three dilutions of each virus suspension were assayed to establish the linearity of the reaction.
RNA isolation and Northern blot analysis
Total cellular RNA was isolated by guanidinium isothiocyanate extraction and cesium chloride density gradient ultracentrifugation as described previously (Bonham et al., 1987) . RNA (5 g) was subjected to Northern blot analysis as previously described (Athas et al., 1995b) . Filters were hybridized to an exogenous FeLV U3 probe to identify viral RNA and subsequently to a probe for ␤-actin to demonstrate uniform loading of the gel.
Electrophoretic mobility shift assays (EMSA)
Nuclear extracts were prepared from K-562 cells using standard procedures (Dignam et al., 1983; Feghali et al., 1994) . Electrophoretic mobility shift assays were performed as previously described (Feghali et al., 1994) using as probe a 96-bp AluI-HincII restriction fragment from the FeLV-945 LTR containing the 21-bp triplication. The restriction fragment had been previously cloned into a plasmid vector; thus for use in this assay, it was released by digestion with EcoRI and HindIII and radiolabeled by end-filling using the Klenow fragment of DNA polymerase. Binding reactions included radiolabeled probe (1 ng) and nuclear extract (3.5 g) from K-562 cells in a 15-l reaction containing 10 mM Tris, pH 7.5;75 mM NaCl; 10 mM EDTA;7% glycerol; 1 mM DTT; and 2 g poly(dI-dC). The mixtures were incubated at 30°C for 30 min and then resolved by 6% polyacrylamide gel electrophoresis in 0.25ϫ TBE buffer (1ϫ TBE buffer is 89 mM Tris base, 89 mM boric acid, and 2 mM EDTA). Gels then were dried at 80°C and exposed to radiographic film for varying periods of time. In some reactions, nonradiolabeled DNA probe was included as a specific competitor or HindIII/HaeIII-digested bacteriophage DNA was included as nonspecific competitor. In that case, the reactants were incubated with competitor DNA for 20 min on ice before addition of the radiolabeled probe.
